Compositions and methods for restoring sensitivity to treatment with her2 antagonists
CA 2459622 C · Owner: A&G Pharmaceutical, Inc. · Inventors: Serrero, Ginette
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods and compositions for restoring growth inhibition sensitivity to a tumor cell resistant to growth inhibition by HER2 antagonists. The methods involve administering a PCDGF antagonist to the cell in an amount effective to restore growth inhibition sensitivity to HER2 antagonists. The invention also provides treatment regimens and therapeutic compositions comprising an HER2 antagonist and a PCDGF antagonist.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 27, 2004 and granted December 13, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 27, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 27, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.